ClinicalTrials.Veeva

Menu
R

Rand Eye Institute | Deerfield Beach, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KSI-301
Aflibercept
Axitinib
UBX1325
OCS-01
EYP-1901
Zimura
GT005
Foselutoclax
AVD-104

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 28 total trials

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling
Macular Neovascularization Secondary to Age-Related Macular Degeneration
Biological: 4D-150 IVT (3E10 vg/eye)
Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.Substudies...

Enrolling
Neovascular (Wet) Age-Related Macular Degeneration
Biological: 4D-150 IVT
Biological: Aflibercept IVT

This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.

Enrolling
Wet Age Related Macular Degeneration
wAMD
Drug: Aflibercept (2.0 mg)
Drug: EYP-1901

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Active, not recruiting
Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of OCS- 01 as compared to Vehicle...

Active, not recruiting
Diabetic Macular Edema
Drug: Dexamethasone ophthalmic suspension (OCS-01)
Drug: Vehicle

The primary purpose of the study is to determine if IVT injections of ANX007 every month reduce vision loss in participants with GA secondary to age-...

Enrolling
Geographic Atrophy
Drug: ANX007
Other: Sham Administration

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

Prospective, single-arm, multicenter, single-masked, pivotal study to Evaluate the Safety and Effectiveness of the Blinker system in Participants wit...

Begins enrollment in 2 months
Ramsay Hunt Syndrome
Facial Palsy
Device: BlinkER device.

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration

Active, not recruiting
Neovascular Age-related Macular Degeneration
Drug: OTX-TKI
Drug: Aflibercept

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration

Active, not recruiting
Neovascular Age-Related Macular Degeneration
Drug: OTX-TKI (axitinib implant)
Drug: Aflibercept

Trial sponsors

Kodiak Sciences logo
4
Bayer logo
E
Ocular Therapeutix logo
U
AbbVie logo
Alcon logo
A
Astellas logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems